



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2017

The Role of Fungi in Atopic Dermatitis

Glatz, Martin ; Bosshard, Philipp ; Schmid-Grendelmeier, Peter

DOI: <https://doi.org/10.1016/j.iac.2016.08.012>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-138153>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Glatz, Martin; Bosshard, Philipp; Schmid-Grendelmeier, Peter (2017). The Role of Fungi in Atopic Dermatitis. *Immunology and Allergy Clinics of North America*, 37(1):63-74.

DOI: <https://doi.org/10.1016/j.iac.2016.08.012>

The Role of Fungi in Atopic Dermatitis

Martin Glatz^{1,2}, Philipp Bosshard³, Peter Schmid-Grendelmeier^{1,2}

¹ Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland

² Christine-Kühne Center for Allergy Research and Education CK-CARE

³ Mycology Laboratory, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland

Correspondence to:

Martin Glatz, MD

Allergy Unit, Department of Dermatology, University Hospital of Zurich

Gloriastrasse 31, 8091 Zurich, Switzerland

Email: martin.glatz@usz.ch

Introduction

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. The prevalence of AD has tripled within the last three decades, currently affecting up to 30% of children and 10% of adults in industrial countries ¹. The pathogenesis of AD is not fully understood. Besides some other environmental factors, the skin microbiome - the community of microorganisms colonizing the skin - has been attributed a pathogenic role in AD. The altered skin colonization with microorganisms in AD patients versus healthy individuals has been extensively investigated for bacteria, in particular *Staphylococcus aureus*. These aspects are highlighted in the chapter of Infectious Complications in Atopic Dermatitis by Peck Y Ong in this issue. Recently, microbiome research extended on the possible pathogenic role of fungi in AD. This research has been focused on the commensal lipophilic yeast *Malassezia* spp. because (i) AD patients are more frequently sensitized to *Malassezia* spp. than healthy individuals, and (ii) AD patients may benefit from an antifungal therapy that is effective against *Malassezia* spp. This led to the publication of a plethora of studies on the possible role of *Malassezia* spp. in the development and course of AD. Several studies applied culture or molecular methods such as polymerase chain reaction to assess possible differences in the epidemiology of *Malassezia* spp. skin colonization between healthy and diseased skin such as AD. However, these studies obtained variable results presumably owing to methodical inconsistencies such as skin sampling from inconsistent body sites and the use of different cultivation methods or PCR primers. Next

generation sequencing is a molecular method that has been recently introduced into skin microbiome research, as it gives information on skin microbial communities that is complementary to cultivation or PCR. As for the bacterial skin microbiome, next generation sequencing revealed that the skin fungal microbiome is highly specific for a particular body site ². Therefore, comparing the prevalence of *Malassezia* species between different body sites sampled in different studies will give unreliable results. Also, the epidemiological studies used different culture media to detect *Malassezia* species. We [unpublished data] and others have shown that different culture media favor the growth of particular *Malassezia* species ³⁻⁶. Therefore, the use of only one or a few types of culture media does not necessarily depict the whole spectrum of *Malassezia* species present in a sample. Surprisingly, studies comparing healthy individuals and AD patients did not reveal a difference in the frequency of skin colonization with *Malassezia* spp. between both groups ⁶. It therefore appears as a medical conundrum how *Malassezia* spp. on the one hand seems to contribute to the pathogenesis of AD patients and on the other hand is a commensal on healthy skin. Recent research at least partially elucidated the possible pathogenetic role of *Malassezia* spp. in AD.

Epidemiology

The skin is an ecosystem and harbors diverse and body site-specific microbial communities, which have been termed the skin microbiome. The phylogenetic

profiling of the skin microbiome revealed that fungi are part of the normal skin flora at all body sites and comprise 1-22% of the phylogenetic composition of the skin microbiome ⁷. *Malassezia* spp. almost exclusively comprises to the fungal flora of the healthy skin on most body sites. It is therefore the main eukaryotic member of the microbial flora of the skin ^{6, 7}. *Malassezia* spp. is a genus of lipophilic yeasts (Figure 1). Most of the *Malassezia* species lack the genes for fatty acid synthase genes and therefore rely on exogenous fatty acid sources to satisfy their nutritive requirement ⁸. *M. pachydermatis*, a species isolated from dogs and other animals ⁹, is the only known *Malassezia* species that grows in the absence of exogenous lipids ⁸. Their need for exogenous lipids explains the predilection of *Malassezia* species for seborrheic skin sites, such as the head and neck. The taxonomy of *Malassezia* spp. has been defined in its current form in 1996, based on morphology, ultrastructure, physiology and molecular biology ¹⁰. The genus *Malassezia* spp. belongs to the phylum Basidiomycota and currently encompasses 14 species that have been isolated from human and animal skin (Table 1). Two of these species, *M. globosa* and *M. restricta*, are consistently found on healthy skin of individuals from the U.S. and Europe, and are identified on almost all body sites ^{2, 6}. However, epidemiological studies indicated a geographical variation in the distribution of particular *Malassezia* species, presumably owing to climate factors. For example, *M. sympodialis* has been reported in studies from Canada, Russia and Sweden as the most frequent species, whereas in Japan *M. furfur* was the most common species ⁶.

Table 1. Currently identified *Malassezia* species (modified from ¹¹⁻¹³)

<i>Malassezia</i> species	Isolated from human skin	Isolated from animal skin	Description as species (year)
<i>M. caprae</i>		X	2007
<i>M. cuniculi</i>		X	2011
<i>M. dermatitis</i>	X		2002
<i>M. equina</i>		X	2007
<i>M. furfur</i>	X	X	1889
<i>M. globosa</i>	X	X	1996
<i>M. japonica</i>	X		2003
<i>M. nana</i>		X	2004
<i>M. obtusa</i>	X		1996
<i>M. pachydermatis</i>		X	1925
<i>M. restricta</i>	X		1996
<i>M. slooffiae</i>	X	X	1996
<i>M. sympodialis</i>	X	X	1990
<i>M. yamatoensis</i>	X		2004

Risk factors for sensitization to *Malassezia* spp.**Sensitization to *Malassezia* spp. may correlate with the severity of atopic dermatitis**

As *Malassezia* spp. is part of the healthy skin flora, it appears reasonable that it regularly interacts with skin immune cells such as dendritic cells or lymphocytes. Accordingly, *Malassezia* spp.-specific IgG and IgM antibodies can be regularly detected in healthy individuals ⁸. In contrast, the rate of IgE-mediated sensitization to *Malassezia* spp. is very low or even absent among individuals with healthy skin. In contrast, a high proportion of AD patients appears sensitized

to this yeast ¹⁴, as demonstrated by positive skin prick tests in up to 80% of adult AD patients ¹⁵⁻¹⁸. Because skin test extracts for *Malassezia* spp. are not yet commercially available and standardized it is nearly impossible to compare the results of different skin prick test studies. Therefore, the detection of *Malassezia* spp.-specific serum IgE is desirable to assess sensitization. Fortunately, a standardized kit (ImmunoCAP® m70, Phadia) for the detection of *Malassezia* spp.-specific serum IgE is available, which is based on the ATCC strain 42132. Recently, a new test kit (ImmunoCAP® m227) has been introduced which contains the antigens of several *Malassezia* spp. and therefore is very sensitive ¹⁹. Using these commercial kits, *Malassezia* spp.-specific IgE are found in up to one third of children ^{15, 20-22} and two thirds of adults with AD ^{15, 19, 22-24}. Accordingly, a recent study on 176 adult AD patients found higher rates of IgE-mediated *Malassezia* sensitization among patients with severe compared to moderate AD ²⁵. These high rates of *Malassezia* spp.-specific IgE detection in adult AD patients are consistent with the rates of positive *Malassezia* spp. skin prick tests in this population (see above). Interestingly, sensitization rates against *Malassezia* spp. are particularly higher in patients with head and neck type of AD ¹⁹. This may be attributed to the lipophilic properties and hence the predilection of this yeast for seborrheic skin areas such as the head and neck region. Therefore some authors assume that *Malassezia* spp. plays a pathogenic role particularly in this clinical subtype of AD ²⁶.

Pathophysiology

The pathophysiologic mechanisms underlying this high frequency of *Malassezia* spp.-sensitization in AD patients compared to healthy individuals remain to be elucidated. It appears, that several endogenous factors such as the dysfunctional skin barrier or aberrations in the skin immune system of AD patients, as well as environmental factors influence the skin colonization with *Malassezia* spp. and the IgE-mediated sensitization to this yeast²⁷. This sensitization to *Malassezia* spp. may correlate to the severity of AD particularly in adults as recently shown in two studies on 132 children and 128 adults with AD^{22 28}. The lower frequency of *Malassezia* spp. sensitization in children compared to adults and therefore the missing correlation between AD severity and *Malassezia* spp.-specific IgE in children might owe to the poor growth conditions for *Malassezia* spp. in children compared to adults. Children produce low amounts of sebum in their skin, and sebum production increases during puberty and is high until the age of 50²⁹. Hence, the growths conditions for *Malassezia* spp. on pediatric skin are worse than on adult skin, and this could be the reason that sensitization to *Malassezia* spp. preferably occurs in adulthood²². Several allergens of *Malassezia* spp. elucidate a specific IgE response. To date, at least 14 allergens of three *Malassezia* species, namely *M. furfur*, *M. sympodialis* and *M. globosa*, are characterized on a molecular basis³⁰ (Table 2), and 13 of these allergens are listed in the official allergen nomenclature list (<http://www.allergen.org>). These allergens may be released to a higher amount in the environment of atopic skin. For example, the allergen Mala s 12, is released in an higher amount at pH 6.0 that represents conditions of atopic skin, than in the more acidic environment of

pH 5.5 of healthy skin ³¹. It remains unclear if the IgE response plays a pathogenic role in AD or rather serves as a marker for the severity of AD, but the some possible mechanisms how *Malassezia* spp. allergens induce inflammation in atopic skin have been elucidated in recent years and are described in the following.

Table 2. Allergens from *Malassezia* species and their relevance in atopic dermatitis

Allergen	Source	Mass (kDa)	Function	Sensitization (%)	Comment	Ref
Mala f 2	<i>M. furfur</i>	21	Peroxisomal membrane protein	72		32
Mala f 3	<i>M. furfur</i>	20	Peroxisomal membrane protein	70		32
Mala f 4	<i>M. furfur</i>	35	Mitochondrial malate dehydrogenase	83		33
Mala s 1	<i>M. sympodialis</i>	36		unknown		34
Mala s 5	<i>M. sympodialis</i>	19		unknown		35
Mala s 6	<i>M. sympodialis</i>	18	Cyclophilin	92%		35, 36
Mala s 7	<i>M. sympodialis</i>	22		40-60		35, 37
Mala s 8	<i>M. sympodialis</i>	16		40-72		35, 37
Mala s 9	<i>M. sympodialis</i>	11		24-36		35, 37
Mala s 10	<i>M. sympodialis</i>	86	Heat shock protein70	69		38
Mala s 11	<i>M. sympodialis</i>	23	Manganese superoxide dismutase	43-75	Induces dendritic cell maturation, release of IL-6, IL-8, IL-12p70, TNF- α by dendritic cells, auto-reactive T cells against human	39-42

					homologe	
Mala s 12	<i>M. sympodialis</i>	67	Glucose-methanol-choline oxidoreduktase	62		43
Mala s 13	<i>M. sympodialis</i>	13	Thioredoxin	50	Induces auto-reactive T cells against human homologe,	44, 45
MGL_1304	<i>M. globosa</i>	17		62	Induces degranulation of mast cells, IL-4 release by basophils	46, 47

***Malassezia* spp. interacts with the skin immune system**

Prior studies indicated that *Malassezia* spp. interacts with various types of human skin and immune cells. This induces a pro-inflammatory immune response by these immune cells, which seems to contribute to the inflammation during AD flares. It is still unclear how the interaction between *Malassezia* spp. cells and host cells occur, but some different mechanisms have been postulated. First, *Malassezia* spp. penetrated the impaired skin barrier, which is typical for AD patients. In the epidermis and dermis, *Malassezia* spp. is recognized by keratinocytes and immune cells such as Langerhans cells, dermal dendritic cells, natural killer cells and fibroblasts ⁴⁸. A second possible mechanism of *Malassezia* spp. – human cell interaction might be mediated by proteins of *Malassezia* spp. that are packed and released in nanovesicles ⁴⁹. It was demonstrated that these nanovesicles stimulate dendritic cells and mast cells to release of TNF-alpha, IL-6, IL-8, IL-10 and IL-12p70 ^{40, 50}. These cytokines may contribute to skin inflammation in AD. Some other authors suggest that Toll-like receptors (TLRs) such as TLR2 recognize *Malassezia* spp. ⁵¹. TLRs are members of the large family of pattern recognition receptors, which play a key role in the innate immune system as they recognize molecules that are commonly shared by pathogens. Some recent findings substantiated the relevance of TLRs for the immune response of human cells against *Malassezia* spp. For example, *Malassezia* spp. induces the expression of TLR2 and TLR4 on human keratinocytes ⁵² and human dendritic cells ⁴⁸, inducing the production human beta

defensin 2 and CXLC8⁵³ (Figure 2). Another possible mechanism could be the activation of the NLRP3 inflammasome in skin dendritic cells by *Malassezia* spp. This leads to the release of pro-inflammatory cytokines such as production of IL-1beta, and IL-4, IL-5, IL-13 which are key players in the pathogenesis of AD⁵⁴⁻⁵⁶ (Figure 2).

We have above mentioned the IgE-mediated sensitization to various *Malassezia* spp. allergens. These allergens may also directly stimulate IgE-independent immune mechanisms. For example, Mala s 13 is a fungal thioredoxin that is very similar to its human counterpart (Figure 3). When human CD4⁺ T cells recognize the fungal thioredoxin they may cross-react to the human enzyme which is expressed by human keratinocytes. This will induce a T cell-mediated skin inflammation, which is commonly seen in AD⁴⁵. A similar induction of autoreactive T cells and T cell-mediated inflammation was observed for another *Malassezia* spp. allergen, Mala s 11, which is a manganese-dependent superoxide dismutase. The significance of these allergens for skin inflammation in AD were substantiated by the strong correlation between AD severity and Mala s 11 sensitization⁴¹.

Management and therapeutic approaches with antifungals in AD

The basis of every effective AD therapy is the use of skin emollients. They rehydrate the skin and repair the impaired skin barrier. In case of clinically manifest skin inflammation during AD flares, an anti-inflammatory treatment is necessary. This most commonly requires topical steroids or calcineurin inhibitors. Another promising therapeutic approach is the identification and elimination of

trigger factors such as *Malassezia* spp.²⁷, for example by an anti-fungal therapy. The usefulness of an antifungal therapy for AD has been discussed since many years. Azole antifungals are the most common class of antifungal drugs prescribed for AD patients. In vitro, azole antifungals are effective against *Malassezia* spp.^{29, 57} but susceptibility testing of *M. pachydermatis*, a species most commonly isolated from dogs, showed that strains isolated from dogs with AD were less susceptible to azole antifungals than strains isolated from healthy dogs⁵⁸. In humans, the resistance of *Malassezia* spp. to antifungals has not been investigated to date.

Several trials investigated the effects of topical or systemic azole antifungals on AD patients and compared it to placebo. However, these trials gave somehow ambiguous results. As a clinical experience, the topical application of ketoconazole on the face of patients with AD of the head and neck type improves eczema. However, in a placebo-controlled study the combination of topical miconazole-hydrocortisone cream with ketoconazole shampoo was not superior to hydrocortisone alone in patients with head and neck type AD⁵⁹. The benefit of a systemic antifungal treatment for AD patient has been investigated in a randomized, placebo controlled trial on 36 AD patients treated with ketoconazole versus 39 AD patients treated with placebo. AD severity improved significantly in the ketoconazole group but not in the placebo group⁶⁰. For another trial, a total of 53 AD patients were treated with either two different dosages of itraconazole or placebo. The improvement of AD severity was significantly higher in itraconazole treated patients than in the placebo group⁶¹.

The positive effect of azole antifungals on AD could also owe to the anti-inflammatory properties of ketoconazole or itraconazole, as these drugs inhibit the production of IL-4 and IL-5 by T cells ⁶².

The positive effects of antifungals were not confirmed by another study on 15 AD patients treated with ketoconazole versus 14 AD patients treated with placebo. Both treatment groups received topical steroids. Although AD severity improved in both treatment groups, this improvement was not correlated to ketoconazole but rather to the topical steroids ⁶³. The ambiguous results of these clinical trials might be attributed to a selection bias and low patient numbers. It can be speculated that antifungal therapies are more effective in a particular subgroup of AD, for example in patients with a head-neck type of eczema. More recently published studies were of less quality, for example they comprised retrospective observations and lacked a standardized scoring system to assess the severity of AD ⁶⁴. More randomized, placebo controlled studies on large patient populations are needed to reliably assess the benefit of an antifungal therapy in AD.

In summary, there is little doubt that *Malassezia* spp. plays a role in AD as it may interact with the local skin immune responses and barrier function and sensitization against this skin-colonizing yeast can correlate with disease activity; also antifungal therapy shows beneficial effects in some patients. However the pathogenetic mechanism and mutual interaction between *Malassezia* spp. and AD still remain partly unclear and need further investigations.

Figure legends

Figure 1.

Malassezia sympodialis culture isolated from a patient with atopic dermatitis. On Malassezia CHROMagar, grown for 72 hours at 32 °C. (With permission from ⁶⁵)

Figure 2.

Proposed mechanisms by which *Malassezia spp.* contributes to skin inflammation in atopic dermatitis (AD) patients. The increased pH in atopic skin contributes to increased allergen release by *Malassezia spp.* These allergens, supposedly together with whole *Malassezia spp.* cells, penetrate the epidermis through the disturbed skin barrier in AD patients. *Malassezia spp.* cells and their allergens may be recognized by toll-like receptor 2 expressed on keratinocytes and dendritic cells what elicits the release of pro-inflammatory cytokines.

Malassezia spp. components elicit the production of *Malassezia spp.*-specific IgE antibodies through the dendritic cell and T cell-mediated activation of B cells. These IgE antibodies may also contribute, possibly through mast cells, to the inflammation in atopic skin. Finally, autoreactive T cells can cross react between fungal and human manganese-dependent superoxide dismutase (MgSOD) and hence sustain skin inflammation. (With permission from ⁶⁵)

Figure 3.

Crystal structure of the *Malassezia sympodialis* thioredoxin Mala s 13 (Courtesy Prof. Reto Crameri, Davos, Switzerland)

REFERENCES

1. Bieber T. Atopic dermatitis. *N Engl J Med* 2008; 358:1483-94.
2. Findley K, Oh J, Yang J, Conlan S, Deming C, Meyer JA, et al. Topographic diversity of fungal and bacterial communities in human skin. *Nature* 2013; 498:367-70.
3. Kaneko T, Makimura K, Abe M, Shiota R, Nakamura Y, Kano R, et al. Revised culture-based system for identification of *Malassezia* species. *J Clin Microbiol* 2007; 45:3737-42.
4. Kaneko T, Makimura K, Sugita T, Yamaguchi H. Tween 40-based precipitate production observed on modified chromogenic agar and development of biological identification kit for *Malassezia* species. *Med Mycol* 2006; 44:227-31.
5. Ashbee HR. Recent developments in the immunology and biology of *Malassezia* species. *FEMS Immunol Med Microbiol* 2006; 47:14-23.
6. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The *Malassezia* genus in skin and systemic diseases. *Clin Microbiol Rev* 2012; 25:106-41.
7. Oh J, Byrd AL, Deming C, Conlan S, Kong HH, Segre JA. Biogeography and individuality shape function in the human skin metagenome. *Nature* 2014; 514:59-64.
8. Saunders CW, Scheynius A, Heitman J. *Malassezia* fungi are specialized to live on skin and associated with dandruff, eczema, and other skin diseases. *PLoS Pathog* 2012; 8:e1002701.
9. Chen TA, Hill PB. The biology of *Malassezia* organisms and their ability to induce immune responses and skin disease. *Vet Dermatol* 2005; 16:4-26.
10. Gueho E, Midgley G, Guillot J. The genus *Malassezia* with description of four new species. *Antonie Van Leeuwenhoek* 1996; 69:337-55.
11. Harada K, Saito M, Sugita T, Tsuboi R. *Malassezia* species and their associated skin diseases. *J Dermatol* 2015; 42:250-7.
12. Cabanes FJ. *Malassezia* yeasts: how many species infect humans and animals? *PLoS Pathog* 2014; 10:e1003892.
13. Gueho E, Boekhout Y, Begerow D. Biodiversity, phylogeny and ultrastructure Berlin, Heidelberg: Springer; 2010.
14. Johansson C, Sandstrom MH, Bartosik J, Sarnhult T, Christiansen J, Zargari A, et al. Atopy patch test reactions to *Malassezia* allergens differentiate subgroups of atopic dermatitis patients. *Br J Dermatol* 2003; 148:479-88.
15. Scalabrin DM, Bavbek S, Perzanowski MS, Wilson BB, Platts-Mills TA, Wheatley LM. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. *J Allergy Clin Immunol* 1999; 104:1273-9.
16. Scheynius A, Johansson C, Buentke E, Zargari A, Linder MT. Atopic eczema/dermatitis syndrome and *Malassezia*. *Int Arch Allergy Immunol* 2002; 127:161-9.

17. Zargari A, Eshaghi H, Back O, Johansson S, Scheynius A. Serum IgE reactivity to *Malassezia furfur* extract and recombinant *M. furfur* allergens in patients with atopic dermatitis. *Acta Derm Venereol* 2001; 81:418-22.
18. Johansson C, Eshaghi H, Linder MT, Jakobson E, Scheynius A. Positive atopy patch test reaction to *Malassezia furfur* in atopic dermatitis correlates with a T helper 2-like peripheral blood mononuclear cells response. *J Invest Dermatol* 2002; 118:1044-51.
19. Brodska P, Panzner P, Pizinger K, Schmid-Grendelmeier P. IgE-mediated sensitization to *malassezia* in atopic dermatitis: more common in male patients and in head and neck type. *Dermatitis* 2014; 25:120-6.
20. Lange L, Alter N, Keller T, Rietschel E. Sensitization to *Malassezia* in infants and children with atopic dermatitis: prevalence and clinical characteristics. *Allergy* 2008; 63:486-7.
21. Kekki OM, Scheynius A, Poikonen S, Koskinen A, Kautiainen H, Turjanmaa K. Sensitization to *Malassezia* in children with atopic dermatitis combined with food allergy. *Pediatr Allergy Immunol* 2013; 24:244-9.
22. Glatz M, Buchner M, von Bartenwerffer W, Schmid-Grendelmeier P, Worm M, Hedderich J, et al. *Malassezia* spp.-specific Immunoglobulin E Level is a Marker for Severity of Atopic Dermatitis in Adults. *Acta Derm Venereol* 2014.
23. Sandstrom Falk MH, Faergemann J. Atopic dermatitis in adults: does it disappear with age? *Acta Derm Venereol* 2006; 86:135-9.
24. Ramirez de Knott HM, McCormick TS, Kalka K, Skandamis G, Ghannoum MA, Schluchter M, et al. Cutaneous hypersensitivity to *Malassezia sympodialis* and dust mite in adult atopic dermatitis with a textile pattern. *Contact Dermatitis* 2006; 54:92-9.
25. Mittermann I, Wikberg G, Johansson C, Lupinek C, Lundeborg L, Crameri R, et al. IgE Sensitization Profiles Differ between Adult Patients with Severe and Moderate Atopic Dermatitis. *PLoS One* 2016; 11:e0156077.
26. Faergemann J. Atopic dermatitis and fungi. *Clin Microbiol Rev* 2002; 15:545-63.
27. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *Allergy* 2006; 61:969-87.
28. Zhang E, Tanaka T, Tajima M, Tsuboi R, Kato H, Nishikawa A, et al. Anti-*Malassezia*-Specific IgE Antibodies Production in Japanese Patients with Head and Neck Atopic Dermatitis: Relationship between the Level of Specific IgE Antibody and the Colonization Frequency of Cutaneous *Malassezia* Species and Clinical Severity. *J Allergy (Cairo)* 2011; 2011:645670.
29. Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of *Malassezia* in atopic dermatitis affecting the head and neck of adults. *J Am Acad Dermatol* 2009; 60:125-36.
30. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, et al. EAACI Molecular Allergology User's Guide. *Pediatr Allergy Immunol* 2016; 27 Suppl 23:1-250.

31. Selander C, Zargari A, Mollby R, Rasool O, Scheynius A. Higher pH level, corresponding to that on the skin of patients with atopic eczema, stimulates the release of *Malassezia sympodialis* allergens. *Allergy* 2006; 61:1002-8.
32. Yasueda H, Hashida-Okado T, Saito A, Uchida K, Kuroda M, Onishi Y, et al. Identification and cloning of two novel allergens from the lipophilic yeast, *Malassezia furfur*. *Biochem Biophys Res Commun* 1998; 248:240-4.
33. Onishi Y, Kuroda M, Yasueda H, Saito A, Sono-Koyama E, Tunasawa S, et al. Two-dimensional electrophoresis of *Malassezia* allergens for atopic dermatitis and isolation of Mal f 4 homologs with mitochondrial malate dehydrogenase. *Eur J Biochem* 1999; 261:148-54.
34. Schmidt M, Zargari A, Holt P, Lindbom L, Hellman U, Whitley P, et al. The complete cDNA sequence and expression of the first major allergenic protein of *Malassezia furfur*, Mal f 1. *Eur J Biochem* 1997; 246:181-5.
35. Lindborg M, Magnusson CG, Zargari A, Schmidt M, Scheynius A, Crameri R, et al. Selective cloning of allergens from the skin colonizing yeast *Malassezia furfur* by phage surface display technology. *J Invest Dermatol* 1999; 113:156-61.
36. Fluckiger S, Fijten H, Whitley P, Blaser K, Crameri R. Cyclophilins, a new family of cross-reactive allergens. *Eur J Immunol* 2002; 32:10-7.
37. Rasool O, Zargari A, Almqvist J, Eshaghi H, Whitley P, Scheynius A. Cloning, characterization and expression of complete coding sequences of three IgE binding *Malassezia furfur* allergens, Mal f 7, Mal f 8 and Mal f 9. *Eur J Biochem* 2000; 267:4355-61.
38. Andersson A, Scheynius A, Rasool O. Detection of Mala f and Mala s allergen sequences within the genus *Malassezia*. *Med Mycol* 2003; 41:479-85.
39. Andersson A, Rasool O, Schmidt M, Kodzius R, Fluckiger S, Zargari A, et al. Cloning, expression and characterization of two new IgE-binding proteins from the yeast *Malassezia sympodialis* with sequence similarities to heat shock proteins and manganese superoxide dismutase. *Eur J Biochem* 2004; 271:1885-94.
40. Vilhelmsson M, Johansson C, Jacobsson-Ekman G, Crameri R, Zargari A, Scheynius A. The *Malassezia sympodialis* allergen Mala s 11 induces human dendritic cell maturation, in contrast to its human homologue manganese superoxide dismutase. *Int Arch Allergy Immunol* 2007; 143:155-62.
41. Schmid-Grendelmeier P, Fluckiger S, Disch R, Trautmann A, Wuthrich B, Blaser K, et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. *J Allergy Clin Immunol* 2005; 115:1068-75.
42. Guarneri F, Costa C, Foti C, Hansel K, Guarneri C, Guarneri B, et al. Frequency of autoallergy to manganese superoxide dismutase in atopic dermatitis patients: experience of three Italian dermatology centers. *Br J Dermatol* 2015.
43. Zargari A, Selander C, Rasool O, Ghanem M, Gadda G, Crameri R, et al. Mala s 12 is a major allergen in patients with atopic eczema and has sequence similarities to the GMC oxidoreductase family. *Allergy* 2007; 62:695-703.

44. Limacher A, Glaser AG, Meier C, Schmid-Grendelmeier P, Zeller S, Scapozza L, et al. Cross-reactivity and 1.4-A crystal structure of *Malassezia sympodialis* thioredoxin (Mala s 13), a member of a new pan-allergen family. *J Immunol* 2007; 178:389-96.
45. Balaji H, Heratizadeh A, Wichmann K, Niebuhr M, Cramer R, Scheynius A, et al. *Malassezia sympodialis* thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. *J Allergy Clin Immunol* 2011; 128:92-9 e4.
46. Hiragun M, Hiragun T, Ishii K, Suzuki H, Tanaka A, Yanase Y, et al. Elevated serum IgE against MGL_1304 in patients with atopic dermatitis and cholinergic urticaria. *Allergol Int* 2014; 63:83-93.
47. Hiragun T, Ishii K, Hiragun M, Suzuki H, Kan T, Mihara S, et al. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. *J Allergy Clin Immunol* 2013.
48. Buentke E, Scheynius A. Dendritic cells and fungi. *Apmis* 2003; 111:789-96.
49. Gehrmann U, Qazi KR, Johansson C, Hulténby K, Karlsson M, Lundberg L, et al. Nanovesicles from *Malassezia sympodialis* and host exosomes induce cytokine responses--novel mechanisms for host-microbe interactions in atopic eczema. *PLoS One* 2011; 6:e21480.
50. Selander C, Engblom C, Nilsson G, Scheynius A, Andersson CL. TLR2/MyD88-dependent and -independent activation of mast cell IgE responses by the skin commensal yeast *Malassezia sympodialis*. *J Immunol* 2009; 182:4208-16.
51. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol* 2006; 144:1-9.
52. Brasch J, Morig A, Neumann B, Proksch E. Expression of antimicrobial peptides and toll-like receptors is increased in tinea and pityriasis versicolor. *Mycoses* 2014; 57:147-52.
53. Baroni A, Orlando M, Donnarumma G, Farro P, Iovene MR, Tufano MA, et al. Toll-like receptor 2 (TLR2) mediates intracellular signalling in human keratinocytes in response to *Malassezia furfur*. *Arch Dermatol Res* 2006; 297:280-8.
54. Novak N, Leung DY. Advances in atopic dermatitis. *Curr Opin Immunol* 2011; 23:778-83.
55. De Benedetto A, Kubo A, Beck LA. Skin barrier disruption: a requirement for allergen sensitization? *J Invest Dermatol* 2012; 132:949-63.
56. Kistowska M, Fenini G, Jankovic D, Feldmeyer L, Kerl K, Bosshard P, et al. *Malassezia* yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signaling. *Exp Dermatol* 2014.
57. Sugita T, Tajima M, Ito T, Saito M, Tsuboi R, Nishikawa A. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted *Malassezia* species. *J Clin Microbiol* 2005; 43:2824-9.
58. Watanabe S, Koike A, Kano R, Nagata M, Chen C, Hwang CY, et al. In vitro susceptibility of *Malassezia pachydermatis* isolates from canine skin with atopic dermatitis to ketoconazole and itraconazole in East Asia. *J Vet Med Sci* 2014; 76:579-81.

59. Broberg A, Faergemann J. Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomised study. *Acta Derm Venereol* 1995; 75:46-9.
60. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. *Allergy* 2001; 56:512-7.
61. Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. *J Eur Acad Dermatol Venereol* 2004; 18:445-9.
62. Kanda N, Enomoto U, Watanabe S. Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. *J Invest Dermatol* 2001; 117:1635-46.
63. Back O, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2001; 15:34-8.
64. Kaffenberger BH, Mathis J, Zirwas MJ. A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. *J Am Acad Dermatol* 2014; 71:480-3.
65. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The Role of *Malassezia* spp. in Atopic Dermatitis. *J Clin Med* 2015; 4:1217-28.